Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome : Result of a Phase II Clinical Trial
©2022 American Association for Cancer Research..
PURPOSE: Thrombocytopenia is a serious complication of myelodysplastic syndromes (MDS) associated with an increased bleeding risk and worse prognosis. Eltrombopag (ELT), a thrombopoietin receptor agonist, can increase platelet counts and reverse anti-megakaryopoietic effects of lenalidomide (LEN) in preclinical studies. We hypothesized ELT would reduce the incidence of thrombocytopenia in MDS.
PATIENTS AND METHODS: We conducted a Phase II multicenter trial of ELT and LEN in adult patients with low- or intermediate-1-risk MDS with symptomatic or transfusion-dependent anemia or thrombocytopenia (NCT01772420). Thrombocytopenic patients were started on ELT and subsequently treated with LEN after platelets were increased. Patients without thrombocytopenia were started on LEN monotherapy and treated with ELT if they became thrombocytopenic.
RESULTS: Fifty-two patients were enrolled; mean age was 71 years (range 34-93). Overall response rate (ORR) in the intention-to-treat population was 35% (18/52). ELT monotherapy led to ORR of 33.3% (7/21), 29% achieving hematologic improvement (HI)-Platelets, and 24% bilineage responses. LEN monotherapy had 38% ORR (6/16) with all responders achieving HI-Erythroid. Fifteen patients received both ELT and LEN with ORR of 33.3%, 20% achieved HI-Erythroid, and 20% HI-Platelets with 13% bilineage responses. Median duration of response was 40 weeks for ELT (range 8-ongoing), 41 weeks (25-ongoing) for LEN, and 88 weeks (8.3-ongoing) for ELT/LEN. Non-hematologic grade 3-4 treatment-related adverse events were infrequent. Among patients on ELT, 2 had major bleeding events, 1 had a reversible increase in peripheral blasts, and 1 developed marrow fibrosis after 6 years on ELT.
CONCLUSIONS: ELT and LEN are well tolerated and effective in achieving hematologic improvement in patients with low-/intermediate-risk MDS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 29(2023), 1 vom: 04. Jan., Seite 60-66 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gonzalez-Lugo, Jesus D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Benzoates |
|---|
| Anmerkungen: |
Date Completed 10.01.2023 Date Revised 05.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/1078-0432.CCR-22-1457 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347702201 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347702201 | ||
| 003 | DE-627 | ||
| 005 | 20231226034445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-22-1457 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347702201 | ||
| 035 | |a (NLM)36255372 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gonzalez-Lugo, Jesus D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome |b Result of a Phase II Clinical Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2023 | ||
| 500 | |a Date Revised 05.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2022 American Association for Cancer Research. | ||
| 520 | |a PURPOSE: Thrombocytopenia is a serious complication of myelodysplastic syndromes (MDS) associated with an increased bleeding risk and worse prognosis. Eltrombopag (ELT), a thrombopoietin receptor agonist, can increase platelet counts and reverse anti-megakaryopoietic effects of lenalidomide (LEN) in preclinical studies. We hypothesized ELT would reduce the incidence of thrombocytopenia in MDS | ||
| 520 | |a PATIENTS AND METHODS: We conducted a Phase II multicenter trial of ELT and LEN in adult patients with low- or intermediate-1-risk MDS with symptomatic or transfusion-dependent anemia or thrombocytopenia (NCT01772420). Thrombocytopenic patients were started on ELT and subsequently treated with LEN after platelets were increased. Patients without thrombocytopenia were started on LEN monotherapy and treated with ELT if they became thrombocytopenic | ||
| 520 | |a RESULTS: Fifty-two patients were enrolled; mean age was 71 years (range 34-93). Overall response rate (ORR) in the intention-to-treat population was 35% (18/52). ELT monotherapy led to ORR of 33.3% (7/21), 29% achieving hematologic improvement (HI)-Platelets, and 24% bilineage responses. LEN monotherapy had 38% ORR (6/16) with all responders achieving HI-Erythroid. Fifteen patients received both ELT and LEN with ORR of 33.3%, 20% achieved HI-Erythroid, and 20% HI-Platelets with 13% bilineage responses. Median duration of response was 40 weeks for ELT (range 8-ongoing), 41 weeks (25-ongoing) for LEN, and 88 weeks (8.3-ongoing) for ELT/LEN. Non-hematologic grade 3-4 treatment-related adverse events were infrequent. Among patients on ELT, 2 had major bleeding events, 1 had a reversible increase in peripheral blasts, and 1 developed marrow fibrosis after 6 years on ELT | ||
| 520 | |a CONCLUSIONS: ELT and LEN are well tolerated and effective in achieving hematologic improvement in patients with low-/intermediate-risk MDS | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Benzoates |2 NLM | |
| 650 | 7 | |a eltrombopag |2 NLM | |
| 650 | 7 | |a S56D65XJ9G |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Kambhampati, Suman |e verfasserin |4 aut | |
| 700 | 1 | |a Yacoub, Abdulraheem |e verfasserin |4 aut | |
| 700 | 1 | |a Donnellan, William B |e verfasserin |4 aut | |
| 700 | 1 | |a Berdeja, Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Bhagat, Prafulla |e verfasserin |4 aut | |
| 700 | 1 | |a Fehn, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Remy, Cassady |e verfasserin |4 aut | |
| 700 | 1 | |a Jasra, Sakshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kazemi, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Pradhan, Kith |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Mimi |e verfasserin |4 aut | |
| 700 | 1 | |a Mantzaris, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Sica, R Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nishi |e verfasserin |4 aut | |
| 700 | 1 | |a Goldfinger, Mendel |e verfasserin |4 aut | |
| 700 | 1 | |a Kornblum, Noah |e verfasserin |4 aut | |
| 700 | 1 | |a Gritsman, Kira |e verfasserin |4 aut | |
| 700 | 1 | |a Braunschweig, Ira |e verfasserin |4 aut | |
| 700 | 1 | |a Steidl, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Will, Britta |e verfasserin |4 aut | |
| 700 | 1 | |a Shastri, Aditi |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Amit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 29(2023), 1 vom: 04. Jan., Seite 60-66 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:1 |g day:04 |g month:01 |g pages:60-66 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-22-1457 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 1 |b 04 |c 01 |h 60-66 | ||